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INTRODUCTION 
Several series of compounds that include the 
thienopyridine scaffold have been reported as 
inhibitors of known cancer therapeutic targets or 
as inhibitors of cell proliferation in tumor cell lines 
[1,2]. Our research group has already 
synthesized several thieno[3,2-b]pyridine 
derivatives by Pd-catalyzed C-C (Suzuki and 
Sonogashira) and C-N (Buchwald-Hartwig) 
couplings and some of them have presented 
tumor cell growth inhibitory activity in cell lines 
[3-5]. 
In the present work, three new 
aminodiarylamines of the mentioned series were 
synthesized, fully characterized and further 
submitted to evaluation of their growth inhibitory 
effect on three human tumor cell lines, 
representing different tumor models, MCF-7 
(breast adenocarcinoma), NCI-H460 (non-small 
cell lung cancer) and A375-C5 (melanoma), and 
on non-tumor primary cells (porcine liver primary 
cell culture). For the most active compound, a 
study of its effects on normal cell cycle 
distribution and apoptosis induction was 
performed in the NCI-H460 cell line. 
MATERIAL AND METHODS 
Chemistry 
Three di(hetero)arylamines were prepared by 
Buchwald-Hartwig palladium-catalyzed C-N 
coupling of the methyl 3-aminothieno[3,2-
b]pyridine-2-carboxylate with 
bromonitrobenzenes and further reduced in 
almost quantitative yields to the amino 
compounds 1a-c (Scheme 1). 
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Scheme 1. Synthesis of di(heterojarylnitro 
compounds 2 by Buchwald-Hartwig C-N coupling and 
their reduction to the di(heterojarylamines 3. 
Antitumoral activity and toxicity to non-tumor 
cells 
The effect of the aminodiarylamines on the 
growth of three human tumor cell lines (MCF-7, 
A375-C5 and NCI-H460) was studied using the 
sulforhodamine B (SRB) assay. Doxorubicin and 
ellipticine were used as positive controls. 
Furthermore, to investigate the possible toxicity 
of the compounds to non-tumor cells, the in vitro 
cell growth inhibition assay was also performed 
in non-tumor porcine liver primary cells. 
Cell cycle and apoptosis 
The effect of compound 3c on cell cycle profile 
and apoptosis were analysed by flow cytometry 
following propidium iodide (PI) or AnnexinlPI 
staining, respectively. 
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RESULTS AND DISCUSSION 
The effects of the aminodiarylamines on the 
growth of the tumour cell lines (MCF-7, A375-C5 , 
and NCI-H460) are summarized in Table 1. 
Table 1 - GI50 valuesa (~M) obtained for the 
aminodiarylamines 3 and the positive controls. 
3. 3b 3c Standard 
MCF-7 >125 33.80 ± 1,70 1.40 ±O.20 0.04 ± O.oat' 
A375-C5 111.80 ± 5.00 26.00 ± 2.30 1.30 ± 0 .10 0. 13 ± O.Q1 ~ 
NCI-H460 >125 31.30 ± 2.90 1.40 ± DAD 0.09 ± O.OOD 
PLPl >125 61.27 ± 1.83 12.49 ± 0.09 4.19 ± a.Oar 
aResults are given in concentrations that were able to cause 
50% of cell growth inhibition (GI5O) after a continuous 
exposure of 48 h. bpositive control doxorubicin. CPositive 
control ellipticine. 
The aminodiarylam ine 3c provided the lowest 
Glso values (s 1.40 ~M) in all the tested human 
tumor cell lines and did not present toxicity to the 
non-tumor cells at those concentrations. 
The effect of compound 3c on cell cycle profile and 
induction of apdptosis was analyzed in the NCI-H460 
cell line (Figure 2). 
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Figure 2 - Cell cycle analysis of NCI-H460 cells 
treated with compound 3c at its Glso concentrat ion 
(1.4 ~M). Untreated cells (Blank) and compound 
vehicle (OMSO) were used as controls. Results are 
the mean±SEM of three independent experiments . 
This compound changed the cell cycle profile, 
causing a decrease in the percentage of celts in the 
GOIG1 phase. Furthermore, it caused and increase in 
the percentage of ce lls with a sub-G1 DNA content, 
which was suggeslive of apoptosis. 
Results from the Annexin VIP I assay confirmed that 
treatment of NCI-H460 celts with compound 3c 
78 
caused an increase in the percentage of apoptotic 
celts. 
CONCLUSIONS 
The aminodiarylamine 3c gave the lowest Glso 
values in the tested breast , melanoma and non-
smalt cell lung cancer celt lines, and did not 
show toxicity to porcine liver non-tumor cells at 
those concentrations. Furthermore, all the 
compounds presented lower toxicity to porcine 
liver non-tumor cells than the positive control 
elt ipticine. Compound 3c changed the celt cycle 
profile and increased apoptosis of the non-small 
ce ll lung cancer (NCI-H460) cells. 
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